Asia Capital Re (ACR)'s board will not reopen the sales process that led to its $1bn abortive deal with Shenzhen Qianhai Financial Holdings and Shenzhen Investment Holdings, The Insurance Insider understands.
Asia Capital Re (ACR)'s board will not reopen the sales process that led to its $1bn abortive deal with Shenzhen Qianhai Financial Holdings and Shenzhen Investment Holdings, The Insurance Insider understands.